Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$1 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$1 |
| % Margin | – | – | – | 90.2% |
| R&D Expenses | $12 | $13 | $13 | $21 |
| G&A Expenses | $4 | $4 | $4 | -$4 |
| SG&A Expenses | $4 | $4 | $4 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$1 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $16 | $16 | $17 | $29 |
| Operating Income | -$16 | -$16 | -$17 | -$12 |
| % Margin | – | – | – | 1,688% |
| Other Income/Exp. Net | $0 | $0 | $0 | $50 |
| Pre-Tax Income | $0 | $0 | $0 | $37 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $37 |
| % Margin | – | – | – | -5,087.3% |
| EPS | -1.09 | -1.14 | 0 | 1.08 |
| % Growth | 4.4% | – | -100% | – |
| EPS Diluted | -1.09 | -1.14 | 0 | 1.08 |
| Weighted Avg Shares Out | 135 | 135 | 34 | 34 |
| Weighted Avg Shares Out Dil | 135 | 135 | 34 | 34 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $2 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | $0 | -$16 | -$17 | $36 |
| % Margin | – | – | – | -4,896.1% |